Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares fell 4.1% on Wednesday . The stock traded as low as $3.21 and last traded at $3.27, with a volume of 117,369 shares. The stock had previously closed at $3.41.

Several research firms have recently weighed in on DRNA. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Sunday, June 26th. Chardan Capital reaffirmed a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Thursday, April 14th. Jefferies Group reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Leerink Swann reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Finally, Zacks Investment Research raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a report on Thursday, May 12th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $11.95.

The stock’s 50 day moving average is $3.46 and its 200-day moving average is $5.29. The company’s market capitalization is $65.70 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.10. On average, equities research analysts expect that Dicerna Pharmaceuticals Inc. will post ($3.34) EPS for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.